MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Identification of potential oxidative biomarkers in saliva of Parkinson’s disease patients

    J. Rungta, A. Roy, S. Choudhury, S. Ansari, P. Chatterjee, R. Khatun, R. Pramanik, S. Dey, H. Kumar (Kolkata, India)

    Objective: The goal of this study is to ascertain whether salivary oxidative markers are altered in Parkinson’s Disease (PD) and if there is an association of these markers with disease…
  • 2023 International Congress

    Psychometric properties of the Neuropsychiatric Fluctuations Scale: preliminary results in patients with Parkinson’s disease

    C. Rodriguez-Blazquez, I. Debove, S. Murcia, A. Zenger, MM. Kurtis, E. Cubo, C. Falup-Pecurariu, KR. Chaudhuri, H. Reichmann, B. Falkenburger, S. Bostantjopoulou, P. Martinez-Martin, MJ. Forjaz, M. Bereau, P. Krack (Madrid, Spain)

    Objective: To assess the psychometric properties of the Neuropsychiatric Fluctuations Scale (NFS) [1] in patients with Parkinson’s disease (PD) Background: PD presents with non-motor symptoms…
  • 2023 International Congress

    Delayed Diagnosis of Hyperthyroidism in Parkinson’s Disease Patient: A Case Report

    MH. Utami, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

    Objective: To emphasize the importance of thyroid dysfunction as one of the factors that could exacerbate Parkinson's disease (PD) symptoms. Background: Common endocrine disorder associated…
  • 2023 International Congress

    Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion

    A. Antonini, B. Bergmans, D. Kern, P. Odin, L. Bergmann, R. Gupta, J. Homola, M. Shah, J. Zamudio, D. Standaert (Padova, Italy)

    Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…
  • 2023 International Congress

    Cholinergic deficits in Parkinson Disease

    R. Miller, D. Dhavale, J. O’Shea, E. Franklin, N. Cairns, R. Perrin, M. Campbell, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

    Objective: To determine whether loss of cholinergic projections to cortical and limbic regions contributes to the development of dementia in Parkinson’s disease (PD). Background: PD…
  • 2023 International Congress

    Motor subtype stability and cognitive profiles in early Parkinson’s disease

    N. Chia, S. Ng, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the association between motor subtypes’ stability and cognitive assessment scores across three years in early Parkinson’s disease (PD). Background: Past studies have…
  • 2023 International Congress

    WATCH-PD: Longitudinal Digital Assessments in Early Parkinson’s Disease

    T. Kangarloo, ER. Dorsey, P. Auinger, D. Volfson, P. Padmanabhan, Y. Gong, B. Tracey, D. Stephenson, D. Anderson, J. Severson, M. Kostrzebski, P. Wilmot, Y. Pohlson, J. Cosman, J. Adams (Cambridge, USA)

    Objective: To provide a longitudinal profile of early Parkinson’s disease (PD) progression using clinical and digital measures, and to evaluate the extent to which digital…
  • 2023 International Congress

    Trial site factor in Parkinson’s disease (PD) diary non-compliance

    P. Reksoprodjo (Prague, Czech Republic)

    Objective: In this analysis, we wanted to explore if PD diary non-compliance is distributed randomly in the dataset or if it has a tendency to…
  • 2023 International Congress

    The PD-Ballet study: a randomised controlled, single-blinded trial of dance therapy for Parkinson’s, baseline characteristics of the study cohort

    A. Podlewska, L. Batzu, J. Staunton, P. Tall, V. Leta, M. Uribe Mz-Recaman, F. Derbyshire-Fox, A. Hartley, T. Soukup, R. Davis, N. Sevdalis, A. Healey, I. Bakolis, C. Pariante, A. Woods, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To describe baseline characteristics of the cohort of participants recruited to a world-first randomised controlled single blind trial of ballet-based dance intervention for holistic…
  • 2023 International Congress

    Computerized assessment of Handwriting in Parkinson’s Disease Before and After Dopaminergic Medication

    L. Diaz-Feliz, P. Sanz-Cartagena, M. Faundez-Zanuy, J. Arbelo-Gonzalez, P. Garcia-Ruiz (Las Palmas, Spain)

    Objective: Computerized assessment of dysgraphia to evaluate dopaminergic medication effects on the handwriting of newly diagnosed PD patients. Background: Dysgraphia is a common motor symptom…
  • « Previous Page
  • 1
  • …
  • 103
  • 104
  • 105
  • 106
  • 107
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley